Clinical Trials
25 trialsNCT05188573 2026-03-27
EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients
ClearNote Health
Phase NA Withdrawn
NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
NCT06592664 2025-06-06
FORTIFIDE
Lisata Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT04976660 2025-03-18
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Portage Biotech
Phase 1/2 Withdrawn
NCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT06518538 2024-08-15
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT06284226 2024-04-16
CCT-ANK-11
Beijing Kejing Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Withdrawn
NCT04276909 2024-03-13
Feasibility Study of LUM Imaging System for Pancreatic Cancer
Lumicell, Inc.
Phase NA Withdrawn
NCT05465590 2023-12-21
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Mainline Biosciences, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT05702385 2023-12-07
Clinical Utility Study for Exo-PDAC
Qure Healthcare, LLC
Phase NA Withdrawn
NCT05043987 2023-09-07
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Conjupro Biotherapeutics, Inc.
Phase 1 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT03682744 2022-04-06
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT04123574 2022-02-24
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
BioXcel Therapeutics Inc
Phase EARLY_PHASE1 Withdrawn
NCT05181865 2022-02-07
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Flame Biosciences
Phase 1/2 Withdrawn
NCT01510561 2021-08-19
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Gilead Sciences
Phase 1 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT04083651 2021-05-07
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
Phase 2/3 Withdrawn
NCT04151719 2021-05-07
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
Phase 3 Withdrawn
NCT02578459 2019-02-15
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
Flowonix Medical
Phase NA Withdrawn
NCT02446379 2017-01-26
CLIO
Lightpoint Medical Limited
Withdrawn
NCT02310971 2015-04-03
Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Prima BioMed Ltd
Phase 2 Withdrawn
NCT00027521 2012-09-19
Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
Ichor Medical Systems Incorporated
Phase 1 Withdrawn